ストックスクリーナーアプリを入手
301.90
0.81%
-2.46
プレマーケット:
292.84
-9.06
-3.00%
前日終値:
$304.36
開ける：
$301.71
24時間の取引高:
452.50K
Relative Volume:
1.21
時価総額：
$8.08B
収益：
$2.59B
当期純損益:
$168.80M
株価収益率:
49.70
EPS:
6.0748
ネットキャッシュフロー:
$357.20M
1週間 パフォーマンス:
+1.45%
1か月 パフォーマンス:
+6.89%
6か月 パフォーマンス:
-3.47%
1年 パフォーマンス:
+22.52%
1日の値動き範囲:
$300.16
$307.49
1週間の範囲:
$294.42
$307.49
52週間の値動き範囲:
$236.73
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
301.90 | 8.08B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
101.66 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
319.14 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.29 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.77 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.00 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Risk Profile - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Price to earnings forward of Bio-Rad Laboratories, Inc. – BOATS:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
BIO Q1 2026 Earnings: EPS Falls Short of Expectations, Shares Edge LowerEPS Revision Trend - dars.gov.et
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
Bio-Rad Launches Vericheck ddPCR Kits Compatible with QX700 Platform for Biopharma Quality Control and Cell and Gene Therapy Workflows - Cambridge Network
Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth - Ad-hoc-news.de
BIOBio-Rad Laboratories Inc Volatility & Greeks - Finviz
Price to sales forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
BIO.B Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bio-Rad Laboratories outlines long-term growth drivers as life science demand evolves - Ad-hoc-news.de
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO.B Technical Analysis & Stock Price Forecast - Intellectia AI
Bio-Plex Pro Human Cytokine Assays from Bio-Radmultiplex panels for immune research - ad-hoc-news.de
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued - Sahm
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Evaluating Growth Amidst Stable Price Movements - DirectorsTalk Interviews
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW) - TradingView
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative
Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO) - TradingView
Bio-Rad Laboratories Jumps 5.6% Amid Sector-Wide Rally - AlphaStreet
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com
Bio Rad Laboratories Inc (BIOb) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Why Bio-Rad’s Bio-Plex Pro Human Cytokine Screening Panel still matters in the lab - ad-hoc-news.de
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story - Sahm
Bio Rad Laboratories Inc (BIOb) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIOb) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIOb) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIOb) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
大文字化:
|
ボリューム (24 時間):